BioAtla

BioAtla is a San Diego-based biopharmaceutical company that develops novel therapeutics for cancer. Its proprietary Conditionally Active Biologics (CAB) platform yields antibodies or other biologics that can be activated or inactivated under defined physiological conditions, and its Comprehensive Integrated Antibody Optimization (CIAO!) platform supports development of monoclonal antibody and cell-based therapeutics. The company states that its technologies are protected by more than 700 issued patents and patent applications.

BioAtla is a San Diego-based biopharmaceutical company developing novel therapeutics for cancer. Its Conditionally Active Biologics (CAB) platform exploits the unique microenvironment of diseased tissue to more effectively target cancer, yielding antibodies or other biologics that can be activated or inactivated under defined physiological conditions. The company also uses its Comprehensive Integrated Antibody Optimization (CIAO!) platform to develop novel monoclonal antibody and cell-based therapeutics. BioAtla states that these and other proprietary technologies are protected by more than 700 issued patents and patent applications.

Developing novel therapeutics with improved therapeutic index that are safer and more effective for treating cancer.

• 2020.12.15

  Reported2020.12.16

  BioAtla announced pricing of its initial public offering[3]BioAtla 宣布首次公开募股定价prnewswire.com

  BioAtla announced pricing of its initial public offering of 10,500,000 shares at $18.00 per share. The company said the shares were expected to begin trading on the Nasdaq Global Market on December 16, 2020, and that the offering was expected to close on December 18, subject to customary conditions.

Read more

1. 1Home - BioAtlabioatla.com
2. 2About Us - BioAtlabioatla.com
3. 3BioAtla 宣布首次公开募股定价prnewswire.com
4. 4BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Sharesprnewswire.com